Published in J Hematol Oncol on January 25, 2017
(89)Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging (2017) 0.80
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. J Hematol Oncol (2017) 0.77
Clinical applications of PD-L1 bioassays for cancer immunotherapy. J Hematol Oncol (2017) 0.75
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. J Hematol Oncol (2017) 0.75
Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. J Hematol Oncol (2017) 0.75
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol (2017) 0.75
In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade. Exp Hematol Oncol (2017) 0.75
Prognostic significance of PD-L1 expression and (18)F-FDG PET/CT in surgical pulmonary squamous cell carcinoma. Oncotarget (2017) 0.75
PD-L1 protein expression in non-small cell lung cancer based on different immunohistochemical antibodies. J Thorac Dis (2017) 0.75
Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40(+) monocyte differentiation. J Hematol Oncol (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Cancer genome landscapes. Science (2013) 25.33
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
A theory of self-nonself discrimination. Science (1970) 7.99
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol (2004) 7.16
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 6.97
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci U S A (1990) 6.19
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
The future of immune checkpoint therapy. Science (2015) 5.59
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
A new member of the immunoglobulin superfamily--CTLA-4. Nature (1987) 5.10
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 5.05
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity (2004) 4.60
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol (2001) 4.10
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 3.47
Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu Rev Immunol (1983) 3.32
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood (2007) 3.00
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med (2003) 2.66
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell (2015) 2.52
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol (2014) 2.47
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood (2008) 2.41
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol (2003) 2.08
The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med (2011) 2.04
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol (2004) 2.02
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol (2015) 1.90
CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res (2013) 1.90
Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood (2000) 1.76
PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood (2009) 1.74
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 1.67
Costimulation of T cells for tumor immunity. Immunol Today (1993) 1.57
B7-H5 costimulates human T cells via CD28H. Nat Commun (2013) 1.19
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Oncologist (2016) 1.18
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med (2015) 1.14
Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol (2011) 1.13
Ipilimumab: first global approval. Drugs (2011) 1.01
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol (2015) 1.01
Pembrolizumab: first global approval. Drugs (2014) 0.99
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. Oncologist (2016) 0.99
B7 family molecules: novel immunomodulators at the maternal-fetal interface. Placenta (2002) 0.96
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity (2016) 0.96
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med (2016) 0.95
The T cell antigen receptor: "The Hunting of the Snark". Eur J Immunol (2007) 0.93
Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma. Am Health Drug Benefits (2015) 0.89
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol (2016) 0.85
Immunotherapy: it takes a village. Science (2014) 0.82
4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother (2016) 0.81
From the guest editor: Tumor site immune modulation therapy. Cancer J (2014) 0.80
Historical overview of immunological tolerance. Cold Spring Harb Perspect Biol (2012) 0.79
Nods for Atezolizumab and Nivolumab from FDA. Cancer Discov (2016) 0.77
Atezolizumab: First Global Approval. Drugs (2016) 0.76
Revisiting the Discovery of the αβ TCR Complex and Its Co-Receptors. Front Immunol (2014) 0.76
Cancer immunotherapy out of the gate: the 22nd annual Cancer Research Institute International Immunotherapy Symposium. Cancer Immunol Res (2015) 0.76
Adapting conventional cancer treatment for immunotherapy. J Mol Med (Berl) (2016) 0.76
Remembrance of immunology past: conversations with Herman Eisen. Annu Rev Immunol (2015) 0.76
Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol (2015) 0.76